Chimigen Bio Secures Over RMB 100 Million in Series A Financing Led by Longpan Investment to Advance Immunotherapy Pipeline

Investment Circle (ID: pedaily2012) September 23rd news, recently, Chimigen Bio (Chengdu) Co., Ltd. (referred to as:Chimigen Bio) Announced CompletionOver 100 Million Yuan in First Round Financing, this round of financing was led byLapamCapitalLed by LapamCapital, Puhua Capital, Nanjing King-friend Biochemical Pharmaceutical Co.,Ltd. and other institutions followed on the investment. The proceeds of this round will accelerate the advancement of two leading products into clinical trials, and expand the international team and attract professional talents.H&J Capital served as the exclusive financial advisor for Chimigen Bio in this round of financing.

Chimigen BioFounded in August 2021 and located in Chengdu Tianfu International Bio City, Chimigen Bio is an innovative biotechnology company focused on the development of advanced immunotherapies for antiviral and anticancer treatments, committed to overcoming difficult-to-treat diseases with novel therapies.

Founder Dr. Yue Nian ShiDr. Shi, who has been focusing on cancer research for nearly 35 years, is a senior scientist in the field of cancer treatment. He graduated from Beijing Medical University, and in 1984, he was awarded the CUSBEA scholarship by the Ministry of Education to study in the United States. In 1989, he received his Ph.D. in Biochemistry from Dartmouth Medical School. Dr. Shi has served as a professor at the Albert Einstein College of Medicine in New York, the Long Island Jewish Medical Center, and Nanjing Medical University. He also served as the vice president of the Clinical Medical Research Institute of Jiangsu Provincial People's Hospital, where he has long been committed to research in the field of cancer immunotherapy. In addition, Dr. Shi founded several biotechnology/pharmaceutical companies and has accumulated extensive experience in international clinical development of new drugs, medical technology innovation, and corporate management operations.

Chimigen Bio Core Innovative Vaccine Platform——“SynNeogen", with fully independent patents, possesses both antigen and antibody dual properties, capable of simulating the entire process of the human body's natural antigen uptake, processing, and presentation, further inducing a broad immune response with antigen-specific multi-epitopes.

Relying on the "SynNeogen" technology platform, Chimigen Bio can transform antigens that induce immune tolerance into "Neoantigens." This represents a platform-based "Neoantigen" design, which is distinct from neoantigens used in personalized therapies. The redesigned "Neoantigens" can effectively break immune tolerance and rebuild antigen-specific immunity, particularly antigen-specific T-cell immunity (T-Cell Priming), for the development of Therapeutic Vaccines.

Currently, under the support of the "SynNeogen" technology platform, the company has developed a series of antigen-specific immunotherapies targeting viruses and tumors, establishing a globally significant product pipeline with both therapeutic and preventive options. The two lead candidates, respectively addressing unmet clinical needs in hepatitis B and prostate cancer, are expected to enter clinical trials within one year.

Partner of Hejun Capital, Lou YiningStated: "Chimigen Bio takes a global perspective and is committed to original innovation. The 'SynNeogen' platform technology differs from traditional immunotherapy paradigms, featuring a novel and unique design that traces back to the root to explore breakthroughs in immunotherapy. Despite a relatively quiet market environment, Chimigen Bio’s first round of financing still exceeded expectations, which fully demonstrates the extraordinary value of the Chimigen platform and its pipeline. We deeply thank Dr. Shi for his trust in Junren Capital. We look forward to continuously empowering Chimigen Bio by providing full-cycle capital consulting services. We anticipate that Dr. Shi will lead Chimigen Bio to ride the waves and set new trends."

This article is sourced from Pedaily, original text: https://news.pedaily.cn/202209/501133.shtml